Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair DeficiencyÉric Bouffet, Uri Tabori, Roula Farah et al.|Journal of Clinical Oncology|2016Cited by 867
Comprehensive Analysis of Hypermutation in Human CancerBrittany Campbell, Melyssa Aronson, Nicholas Light et al.|Cell|2017Cited by 795
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Michael Osborn et al.|Blood|2014Cited by 102
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human CellsJiil Chung, Cynthia Hawkins, Yosef E. Maruvka et al.|Cancer Discovery|2020Cited by 85
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentLaura N Eadie, Deborah L. White, P Dang et al.|Leukemia|2016Cited by 68